BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Seralutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Seralutinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06274801-535@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Seralutinib: Phase 3 readout est. (NCT06274801)
DESCRIPTION:Seralutinib\, phase 3\, Pulmonary Arterial Hypertension.\nStudy
 : Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PR
 OSERA-EXT)\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/seralutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06274801
URL:https://assetmemo.bio/drug/seralutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
